Tesla Inc
Change company Symbol lookup
Select an option...
TSLA Tesla Inc
WEC WEC Energy Group Inc
PFE Pfizer Inc
T AT&T Inc
BFC Bank First Corp
RIGMF Ridgestone Mining Inc
BAC Bank of America Corp
WFC Wells Fargo & Co
ASB Associated Banc-Corp
WSBF Waterstone Financial Inc
Go

Consumer Discretionary : Automobiles | Large Cap Growth
Company profile

Tesla, Inc., formerly Tesla Motors, Inc., designs, develops, manufactures and sells fully electric vehicles, and energy storage systems, as well as installs, operates and maintains solar and energy storage products. The Company operates through two segments: Automotive, and Energy generation and storage. The Automotive segment includes the design, development, manufacturing, and sales of electric vehicles. The Energy generation and storage segment includes the design, manufacture, installation, and sale or lease of stationary energy storage products and solar energy systems to residential and commercial customers, or sale of electricity generated by its solar energy systems to customers. The Company produces and distributes two fully electric vehicles, the Model S sedan and the Model X sport utility vehicle (SUV). It also offers Model 3, a sedan designed for the mass market. It develops energy storage products for use in homes, commercial facilities and utility sites.

Closing Price
$1,208.66
Day's Change
89.03 (7.95%)
Bid
--
Ask
--
B/A Size
--
Day's High
1,228.00
Day's Low
1,185.60
Volume
(Heavy Day)
Volume:
17,250,115

10-day average volume:
10,613,661
17,250,115

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Inovio Pharmaceuticals, Inc. (INO)

5:38 pm ET May 26, 2020 (BusinessWire) Print

Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.

If you suffered a loss as a result of Inovio's misconduct, click here.

Inovio Pharmaceuticals, Inc. (INO) Accused of False COVID-19 Vaccine Claims

According to the pending class action lawsuit filed against Inovio, on March 11, 2020, the World Health Organization ("WHO") declared the coronavirus COVID-19 outbreak a global "pandemic" due to its extraordinary "speed and scale of transmission." In response to mounting public concern, on February 14, 2020, Inovio's CEO announced on national news that the Company had developed a COVID-19 vaccine "in a matter of about three hours" and re-affirmed this statement two weeks later in a well-publicized meeting with President Trump. As a result, Inovio's stock price more than quadrupled. However, contrary to these claims, on March 9, 2020, Citron Research exposed Inovio's misstatements, calling for an SEC investigation into Inovio's "dangerous claim that they designed a [COVID-19] vaccine in 3 hours." Consequently, Inovio admitted the Company had not developed a COVID-19 vaccine but rather a "vaccine construct." On this news, Inovio's stock price declined to a mere $5.70 per share, representing a 71% decline from the Company's class period high of $19.36 per share.

Inovio Pharmaceuticals, Inc. (INO) Shareholders Have Legal Options

Contact us to learn more: Leo Kandinov (800) 350-6003 lkandinov@robbinsllp.com Shareholder Information Form

Want to be notified if a class action against Inovio settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005868/en/

SOURCE: Robbins LLP

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com 
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.